Cart
sales@molnova.com
GSK8573
CAS No. 1693766-04-9
GSK8573( —— )
Catalog No. M22027 CAS No. 1693766-04-9
GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 29 | In Stock |
|
| 5MG | 30 | In Stock |
|
| 10MG | 48 | In Stock |
|
| 25MG | 91 | In Stock |
|
| 50MG | 142 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK8573
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
-
DescriptionGSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
-
In VitroGSK8573 (1.0 μM) has binding activity to BRD9 with a Kd value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain family.
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorBRD9
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1693766-04-9
-
Formula Weight323.39
-
Molecular FormulaC20H21NO3
-
Purity>98% (HPLC)
-
SolubilityDMSO:22 mg/mL (68.03 mM; Need ultrasonic)
-
SMILESCCCOC1=CC2=C(C=C(N2C=C1)C(C)=O)C1=CC(OC)=CC=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chen P, et al. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. J Med Chem. 2016 Feb 25;59(4):1410-24.
molnova catalog
related products
-
Menin-MLL inhibitor ...
Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, compound 6).
-
GSK620
GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics.
-
BY27
BY27, a potent and selective BET BD2 inhibitor (Ki: 3.1 nM) with anticancer activity, inhibits BD1/BD2 of BRD2, BRD3, BRD4, and BRDT, and suppresses tumor growth.
